May 31, 2018 - Subtotal colectomy. Proctocolectomy. Ostomy. Primary anastomosis. Stricturoplasty. Fistula repair (enteroenteric and enterocutaneous fistula).
A107 POSTOPERATIVE OUTCOMES AMONG USTEKINUMAB TREATED CROHN’S DISEASE PATIENTS: A MULTICENTRE CANADIAN PROVINCIAL EXPERIENCE H. Shim6, C. Ma2, H. Al-Farhan 6, A.K. Aldarmaki6, J. Pang2, C. Seow7, R. Fedorak1, S. Devlin2, L.A. Dieleman4, G.G. Kaplan8, K.L. Novak5, K.I. Kroeker4, B.P. Halloran3, R. Panaccione2 1. Los Alamos National Laboratory, Edmonton, AB, Canada; 2. University of Calgary, Calgary, AB, Canada; 3. Medicine, Divison of Gastroenterology, University Of Alberta , Edmonton, AB, Canada; 4. Medicine, University of Alberta, Edmonton, AB, Canada; 5. Gastroenterology, University of Calgary, Calgary AB, AB, Canada; 6. Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada; 7. Medicine, University of Calgary, Calgary, AB, Canada; 8. Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada Background: Ustekinumab (UST), an anti IL12/23 inhibitor, has been recently approved for the treatment of moderate to severe Crohn’s disease (CD) in Europe and the United States. In Canada, UST has been used off-label for CD patients failing anti-TNF therapy. Aims: We aim to review postoperative safety outcomes for UST-treated CD patients which has not been previously reported. Methods: A retrospective chart review of UST-treated CD patients at two tertiary care academic centres (University of Calgary, University of Alberta) who underwent abdominal surgery between April 1, 2013 and July 31, 2016 was performed. The primary outcome was occurrence of postoperative complications stratified by timing [early (
